West Pharmaceutical Services (WPS) Stock Forecast & Price Target
WPS Analyst Ratings
Strong Buy
6Buy0Hold0Sell
Based on 6 analysts giving stock ratings to West Pharmaceutical Services in the past 3 months
WPS Stock 12 Month Forecast
Average Price Target
EUR 426.93▲(12.23% Upside)Based on 6 Wall Street analysts offering 12 month price targets for West Pharmaceutical Services in the last 3 months. The average price target is EUR 426.93 with a high forecast of EUR 446.42 and a low forecast of EUR 357.14. The average price target represents a 12.23% change from the last price of EUR 380.40.
Past 12 Months12 Month ForecastDec2025Sep2026
HighEUR 446.42
AverageEUR 426.93
LowEUR 357.14
Highest Price TargetHighestEUR 446.42Average Price TargetEUR 426.93Lowest Price TargetLowestEUR 357.14
Detailed List of Analyst Forecasts
Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
| Price Target | Follow | Article | ||||||
|---|---|---|---|---|---|---|---|---|
| Luke Sergott | Barclays | EUR 392.85→EUR 446.42 | buy | 17.36%Upside | Reiterated | 10/30/26 | ||
| Joanne Wuensch | Citi | EUR 367.85→EUR 441.07 | buy | 15.95%Upside | Reiterated | 10/30/26 | ||
 Unknown AnalystNot Ranked | UBS | EUR 388.39→EUR 441.96 | buy | 16.18%Upside | Reiterated | 10/30/26 | ||
| Brendan Smith | TD Cowen | EUR 375.00→EUR 446.42 | buy | 17.36%Upside | Reiterated | 10/30/26 | ||
| Daniel Markowitz CFA | Evercore ISI | EUR 392.85→EUR 428.57 | buy | 12.66%Upside | Reiterated | 10/30/26 | ||
| Kallum Titchmarsh | Morgan Stanley | EUR 325.89→EUR 357.14 | buy | -6.11%Downside | Upgraded | 09/22/26 | ||
| Michael Ryskin | Bank of America Securities | EUR 366.07 | buy | -3.77%Downside | Reiterated | 07/24/26 | ||
| Matt Larew | William Blair | ― | buy | ― | Reiterated | 07/23/26 | ||
| Curtis Moiles | Exane BNP Paribas | EUR 399.10 | buy | 4.92%Upside | Initiated | 07/13/26 | ||
| Paul Knight | KeyBanc | EUR 312.50→EUR 348.21 | buy | -8.46%Downside | Reiterated | 07/02/26 | ||
| Michael Polark | Wolfe Research | EUR 334.82 | buy | -11.98%Downside | Assigned | 06/01/26 | ||
| Justin Bowers | Deutsche Bank | EUR 276.78→EUR 281.25 | buy | -26.07%Downside | Reiterated | 02/13/26 | ||
| Dan Leonard | RBC Capital | EUR 316.96→EUR 303.57 | buy | -20.20%Downside | Reiterated | 02/13/26 | ||
| David Windley | Jefferies | EUR 325.89→EUR 263.39 | buy | -30.76%Downside | Reiterated | 02/10/26 | ||
| Nico Chen | DBS | EUR 285.71 | buy | -24.89%Downside | Reiterated | 01/28/26 |
| Price Target | Follow | Article | ||||||
|---|---|---|---|---|---|---|---|---|
| Luke Sergott | 10/30/26 | EUR 392.85→EUR 446.42 | buy | 17.36%Upside | Reiterated | Barclays | ||
| Joanne Wuensch | 10/30/26 | EUR 367.85→EUR 441.07 | buy | 15.95%Upside | Reiterated | Citi | ||
| Unknown AnalystNot Ranked | 10/30/26 | EUR 388.39→EUR 441.96 | buy | 16.18%Upside | Reiterated | UBS | ||
| Brendan Smith | 10/30/26 | EUR 375.00→EUR 446.42 | buy | 17.36%Upside | Reiterated | TD Cowen | ||
| Daniel Markowitz CFA | 10/30/26 | EUR 392.85→EUR 428.57 | buy | 12.66%Upside | Reiterated | Evercore ISI | ||
| Kallum Titchmarsh | 09/22/26 | EUR 325.89→EUR 357.14 | buy | -6.11%Downside | Upgraded | Morgan Stanley | ||
| Michael Ryskin | 07/24/26 | EUR 366.07 | buy | -3.77%Downside | Reiterated | Bank of America Securities | ||
| Matt Larew | 07/23/26 | ― | buy | ― | Reiterated | William Blair | ||
| Curtis Moiles | 07/13/26 | EUR 399.10 | buy | 4.92%Upside | Initiated | Exane BNP Paribas | ||
| Paul Knight | 07/02/26 | EUR 312.50→EUR 348.21 | buy | -8.46%Downside | Reiterated | KeyBanc | ||
| Michael Polark | 06/01/26 | EUR 334.82 | buy | -11.98%Downside | Assigned | Wolfe Research | ||
| Justin Bowers | 02/13/26 | EUR 276.78→EUR 281.25 | buy | -26.07%Downside | Reiterated | Deutsche Bank | ||
| Dan Leonard | 02/13/26 | EUR 316.96→EUR 303.57 | buy | -20.20%Downside | Reiterated | RBC Capital | ||
| David Windley | 02/10/26 | EUR 325.89→EUR 263.39 | buy | -30.76%Downside | Reiterated | Jefferies | ||
| Nico Chen | 01/28/26 | EUR 285.71 | buy | -24.89%Downside | Reiterated | DBS |
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Best Analysts Covering West Pharmaceutical Services
3 Months
Success Rate8/10 ratings generated profit
80%
Average Return
+14.30%
Copying Matt Larew's trades and holding each position for 3 Months would result in 80.00% of your transactions generating a profit, with an average return of +14.30% per trade.
1 Year
Success Rate5/5 ratings generated profit
100%
Average Return
+37.40%
Copying Brendan Smith's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +37.40% per trade.
2 Years
Success Rate6/6 ratings generated profit
100%
Average Return
+61.45%
Copying Dan Leonard's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +61.45% per trade.
WPS Analyst Recommendation Trends
| Rating | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 |
|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 |
| Buy | 11 | 17 | 14 | 13 | 10 |
| Hold | 8 | 5 | 2 | 2 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 19 | 22 | 16 | 15 | 11 |
In the current month, WPS has received 10 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. WPS average Analyst price target in the past 3 months is 426.93.
WPS Financial Forecast
HighEUR 2.07
ConsensusEUR 2.04
LowEUR 1.99
WPS Earnings Forecast
Next quarter’s earnings estimate for WPS is EUR 2.04 with a range of EUR 1.99 to EUR 2.07. The previous quarter’s EPS was EUR 2.37. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.
HighEUR 740M
ConsensusEUR 736M
LowEUR 733M
WPS Sales Forecast
Next quarter’s sales forecast for WPS is EUR 736.19M with a range of EUR 732.66M to EUR 739.81M. The previous quarter’s sales results were EUR 780.32M. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.
WPS Stock Forecast FAQ
What is DE:WPS’s average 12-month price target, according to analysts?
Based on analyst ratings, West Pharmaceutical Services’s 12-month average price target is €426.93.
What is DE:WPS’s upside potential, based on the analysts’ average price target?
West Pharmaceutical Services has 12.23% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is West Pharmaceutical Services a Buy, Sell or Hold?
West Pharmaceutical Services has a consensus rating of Strong Buy, which is based on 6 buy ratings, 0 hold ratings and 0 sell ratings.
What is West Pharmaceutical Services’s share price target?
The average share price target for West Pharmaceutical Services is €426.93. This is based on 6 Wall Street analysts’ 12-month price targets, issued in the past 3 months. The highest analyst share price target is €446.42, and the lowest forecast is €357.14. The average share price target represents a 12.23% increase from the current price of €380.4.
What do analysts say about West Pharmaceutical Services?
West Pharmaceutical Services’s analyst rating consensus is a Strong Buy. This is based on the ratings of 6 Wall Street analysts.
How can I buy shares of West Pharmaceutical Services?
To buy shares of DE:WPS, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.